

ASX Announcement

04 February 2022

Lapse of Unlisted Share Options

Regeneus Ltd (ASX: RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, advises that the following unlisted share options granted pursuant to Regeneus's option share trust plan have lapsed with the recent redundancy of Chrysostomos Maoudis:

Lapsed Options	Exercise price	Expiry Date
36,090	\$0.10	30-Jun-25

The total number of options remaining on issue following the lapse of the above options are as follows:

Number of Options	Exercise price	Expiry Date
1,250,000	\$0.20	31-Jan-24
3,800,000	\$0.1651	11-May-24
400,000	\$0.10	30-Sep-24
1,543,680	\$0.10	30-Jun-25
1,029,500	\$0.14	31-Aug-25
1,000,000	\$0.1075	31-Aug-25
5,000,000	\$0.10	24-May-26
5,000,000	\$0.10	24-May-26
15,000,000	\$0.10	24-May-26

-ENDS-

About Regeneus

Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza and Sygenus. Visit www.regeneus.com.au for more information.

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Regeneus Ltd

Investor and Media Contact

WE Communications
T: 02 9237 2805
E: WE-AURegeneus@we-worldwide.com